#Israel #MEMS technology #Ziona #MicronJet™ #NanoPass Technologies

NanoPass Technologies Aims to Set New Standards with MicronJet™

In a bold move to broaden its commercial footprint, NanoPass Technologies Ltd. has recently announced the signing of distribution agreements across four significant global markets: Singapore, Mexico, Colombia, and Australia. This expansion signals a pivotal moment for the company, which is already recognized for its pioneering work in Micro-Electro-Mechanical Systems (MEMS) technology, specifically tailored for intradermal delivery.

With the addition of these new markets, NanoPass now operates in over 30 countries, thanks to an earlier establishment of 28 distribution channels across the United States, Canada, and European nations such as Italy, France, Spain, and the UK within the last year. This remarkable growth underscores the company’s ambitious mission to position MicronJet™ as the gold standard globally for intradermal delivery, seamlessly blending comfort, control, and precision across both aesthetic and medical applications.

The MicronJet™ Advantage

MicronJet™ is transforming the landscape of drug delivery by replacing traditional stainless-steel needles with innovative silicon-crystal delivery pyramids that are less than 1 mm in length. This novel design is not only aimed at improving patient comfort but is also crafted to minimize pain and bruising, a common concern with conventional injections. Supported by more than 70 clinical studies and receiving regulatory approvals in significant markets—including the U.S. FDA and the EU CE—the MicronJet™ platform is proving to be a game-changer for various treatments, including aesthetic procedures, dermatological applications, and vaccines.

With two product models available, MicronJet™ 600, which measures 0.6 mm, is designed for a variety of applications like skin rejuvenation, scar treatment, hyperhidrosis management, and local anesthesia. The newly introduced MicronJet™ 800, measuring 0.8 mm, is optimized for the handling of high-viscosity formulations, making it particularly suitable for hair restoration treatments.

Broadening Horizons

As the company navigates through the aesthetics sector for immediate growth, it does not shy away from its deep-tech ambition in the medical field. NanoPass is actively involved in clinical studies with premier pharmaceutical companies, focusing on cutting-edge vaccine developments, immunotherapy advancements, and cell therapy indications targeting major diseases. The commitment to innovating virtually pain-free medical delivery systems, rooted in their proprietary nanotech-based MicronJet™ platform, speaks to their dedication to pushing boundaries in healthcare.

Daniel Levitats, the CEO of NanoPass Technologies, remarked, "This expansion represents a milestone in our evolution from an innovative deep-tech company to a globally recognized commercial entity. Our focus has always been to make MicronJet™ the universal benchmark for intradermal delivery in aesthetic treatments, vaccinations, and advanced therapeutic applications, all through the unrivaled precision of MEMS technology paired with exceptional patient comfort."

Tal Shlezinger, VP of Sales and Marketing, echoed this sentiment, highlighting that MicronJet™ provides healthcare professionals with a proven, evidence-based solution that not only enhances clinical outcomes but also significantly improves the patient experience.

Looking Ahead

The future of MicronJet™ appears bright as NanoPass Technologies embarks on this exciting journey of innovation and expansion. Their aim to revolutionize intradermal delivery and set a global standard is not just a vision but a commitment to enhancing healthcare delivery worldwide. With continual advancements in technology and strong partnerships, NanoPass is poised to lead the charge in redefining the intradermal delivery landscape, making it synonymous with efficiency, safety, and patient-centered care.

For further insights on NanoPass's initiatives and the MicronJet™ platform, please visit NanoPass Technologies.